Replicel Life Sciences Inc (RP) NPV
Replicel Life Sciences Inc is a Canada-based regenerative medicine company. It develops autologous cell therapies that treat functional cellular deficits. Its product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse. RCH-01 also utilizes dermal sheath cup cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to control intradermal (dermis), subcutaneous (fat) or intramuscular injections. It is designed to support the injection of RCH-01 and RCS-01 cell therapy products. The injector has applications for dermatological procedures requiring injections of specific volumes of material at specific depths, including cellular products, fillers and collagen injections.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.